BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

NDA FilingapprovedBBP-418Positive

AI Analysis

Summary

BridgeBio Pharma announced FDA acceptance and priority review designation for its NDA of BBP-418, a therapy for LGMD2I/R9, a rare genetic muscle disorder.

Outcome Details

FDA acceptance and priority review granted

Importance:8/10

Sentiment:

0.80

FDANDAPriority ReviewRare DiseaseGenetic Disorder

Related Companies

$BBIO

Read the original article

Published by Drugs.com New Drug Applications on May 27, 2026 8:05 PM

Read Original